Technical Analysis for CTIC - Cell Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 0.844 4.43% 0.04
CTIC closed up 4.43 percent on Friday, May 24, 2019, on 66 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical CTIC trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.21%
NR7 Range Contraction -2.21%
Inside Day Range Contraction -2.21%
20 DMA Resistance Bearish -4.64%
Pocket Pivot Bullish Swing Setup -2.74%
Lower Bollinger Band Walk Weakness -2.74%
New Downtrend Bearish 5.49%
Lower Bollinger Band Walk Weakness 5.49%
Below Lower BB Weakness 5.49%
Lower Bollinger Band Touch Weakness 5.49%

Older signals for CTIC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Cancer Chemical Compounds Organic Compounds Cancer Treatments Ovarian Cancer Acute Myeloid Leukemia Antibody Drug Conjugates Ethers Seattle Genetics Head And Neck Cancer Pyrrolidines Treatment Of Ovarian Cancer Treatment Of Acute Myeloid Leukemia Myelofibrosis Triple Negative Breast Cancer Camidanlumab Tesirine Pacritinib Pixantrone Treatment Of Head And Neck Cancer
Is CTIC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.36
52 Week Low 0.6
Average Volume 208,793
200-Day Moving Average 1.3801
50-Day Moving Average 0.9553
20-Day Moving Average 0.902
10-Day Moving Average 0.8433
Average True Range 0.0657
ADX 27.05
+DI 14.9504
-DI 23.2647
Chandelier Exit (Long, 3 ATRs ) 0.8229
Chandelier Exit (Short, 3 ATRs ) 0.9731
Upper Bollinger Band 1.0316
Lower Bollinger Band 0.7724
Percent B (%b) 0.28
BandWidth 28.736142
MACD Line -0.0392
MACD Signal Line -0.0355
MACD Histogram -0.0037
Fundamentals Value
Market Cap 26.78 Million
Num Shares 31.7 Million
EPS -1.88
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 2.78
Price-to-Book 2.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.96
Resistance 3 (R3) 0.97 0.93 0.94
Resistance 2 (R2) 0.93 0.90 0.93 0.94
Resistance 1 (R1) 0.89 0.88 0.91 0.88 0.93
Pivot Point 0.85 0.85 0.87 0.85 0.85
Support 1 (S1) 0.81 0.82 0.83 0.80 0.76
Support 2 (S2) 0.78 0.81 0.77 0.75
Support 3 (S3) 0.73 0.78 0.75
Support 4 (S4) 0.73